At-BC8-B10 Trial Before Stem Cell Transplant
Phase 1/2
75
about 11 years
18–75
1 site in WA
About this study
This trial is testing a treatment called At-BC8-B10 before donor stem cell transplant in people with high-risk leukemia. The goal is to find the best dose of this treatment and see how it affects patients.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Pretargeted Radioimmunotherapy
- 2.Receive Total-Body Irradiation
- 3.Take Cyclosporine
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ciclosporin, Antineoplastic Agent [TC] (Nucleic Acid Synthesis Inhibitors), Immunological Agents (Enzyme Inhibitors)
injection, intravenous, injection (Injection)
Primary: Incidence of grades III/IV Bearman regimen-related toxicity
Secondary: Disease-free survival, Non-relapse mortality, Overall survival
diagnostic, imaging, radiation
Oncology